Biagio Ricciuti, MD, Talks About Prolonged Response to Pembrolizumab Monotherapy in PD-L1–High NSCLC

Video

Biagio Ricciuti, MD, spoke about the 3-year follow-up and prolonged survival benefit in patients with non–small cell lung cancer who had very high PD-L1 expression of 90% or more.

Biagio Ricciuti, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute spoke with CancerNetwork® at the 2022 American Society of Clinical Oncology Annual Meeting, about patients with non–small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 90% or more who had a prolonged response compared with those who had TPS of 50% to 89%.

At the median follow-up of 42.6 months, the median progression-free survival (PFS) in the entire cohort was 5.1 months and the median overall survival (OS) was 19.0 months. Median PFS in expression groups of 90% or more vs 50% to 89% was 6.0 months and 4.5 months, respectively (HR, 0.67; P <.001) and median OS was 30.2 months vs 16.9 months (HR, 0.66; P <.01).

Transcript:

At the 3-year follow-up analysis of the retrospective multicenter study of patients with PD-L1 expression 90% or greater, [patients had] a response rate of 47% which was significantly higher compared with the 32% response rate we observed in the patient cohort with expression of 50% to 80%. This difference in response rate at 3 years translated to a significantly longer median PFS and OS. The median OS was almost 30 months among patients with TPS expression 90% or greater as opposed to 17 months in patients with PD-L1 expression of 50%. The outcomes nearly doubled in this patient population. This suggests a benefit in patients with high PD-L1 expression when compared with chemotherapy. The clinical trial [results were] likely driven by the subset of patients with very high PD-L1 expression. This also suggests that PD-L1 expression acts as a more continuous variable.

Reference

Ricciuti B, Elkrief A, Alessi J, et al. Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab. J Clin Oncol. 2022;40(suppl 16):9043. doi: 10.1200/JCO.2022.40.16_suppl.9043

Recent Videos
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
Related Content